(Reuters) -The European Medicines Agency’s (EMA) safety committee has concluded that a potentially dangerous eye condition is a very rare side effect of Novo Nordisk’s popular treatments Ozempic and Wegovy, it said on Friday.
The condition may affect up to 1 in 10,000 people taking semaglutide, the chemical name for Wegovy and Ozempic, the EMA said.
(Reporting by Manas Mishra in Bengaluru; Editing by Shilpi Majumdar)
